Atara Biotherapeutics (ATRA)
(Delayed Data from NSDQ)
$9.02 USD
+0.92 (11.36%)
Updated Jul 10, 2024 04:00 PM ET
After-Market: $9.03 +0.01 (0.11%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth C Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ATRA 9.02 +0.92(11.36%)
Will ATRA be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ATRA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ATRA
Biogen (BIIB) to Buy HI-Bio to Expand Rare Disease Pipeline
GSK Studies on Depemokimab for Severe Asthma Meet Primary Goals
ATRA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Atara Biotherapeutics (ATRA) Reports Q1 Loss, Tops Revenue Estimates
Femasys Inc. (FEMY) Reports Q1 Loss, Misses Revenue Estimates
Dynavax Technologies (DVAX) Reports Q1 Loss, Misses Revenue Estimates
Other News for ATRA
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Atara Biotherapeutics To Participate at the Stifel Virtual Cell Therapy Forum
Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) Wins Prix Galien International Award for Best Product for Orphan/Rare Diseases
Atara Biotherapeutics trading halted, news pending
Why Ovid Therapeutics Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session